BioVersys Receives CARB-X Award of up to US$ 8.92 Million for Development of Novel Antimicrobial Therapies
For development of first-in-class stand-alone anti-virulence small molecule drugs – a paradigm shift in AMR therapy CARB-X funds BioVersys up to US$ 8.92 million to support the development of first-in-class anti-virulence small molecule drugs that disarm bacteria, opening the door for a paradigm shift in AMR therapy BASEL, Switzerland, October 29, 2019 — BioVersys AG, […]